Physician profile
Jason Matthew Hafron
NPI 1255483277
$490,291.22
in general payments reported to CMS, 2019-2025
67 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $57K · 2021: $65K · 2022: $73K · 2023: $67K · 2024: $47K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $91K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Honoraria: $23K · Food and Beverage: $11K · Travel and Lodging: $4,425 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $91,421.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,460.00 |
| Honoraria | $23,300.00 |
| Food and Beverage | $10,571.63 |
| Travel and Lodging | $4,425.34 |
| Education | $129.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $93,097.58 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Dendreon Pharmaceuticals LLC | $50,812.66 | 2019-2025 | Provenge |
| Pfizer INC. | $45,004.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $38,364.73 | 2023-2025 | Pluvicto |
| Astellas Pharma US INC | $29,510.07 | 2019-2025 | Xtandi, Myrbetriq |
| Amgen INC. | $28,706.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27,041.60 | 2019-2025 | |
| Urogen Pharma, INC. | $25,642.16 | 2020-2025 | Jelmyto |
| Astrazeneca Pharmaceuticals Lp | $20,153.94 | 2019-2025 | Truqap, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $19,995.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Tolmar Pharmaceuticals, INC. | $13,909.65 | 2019-2022 | |
| Blue Earth Diagnostics | $13,892.11 | 2019-2025 | Posluma |
| Myriad Genetic Laboratories, INC. | $12,547.74 | 2021-2025 | Prolaris, Myrisk |
| Janssen Global Services, LLC | $10,780.00 | 2021-2025 | Erleada |
| Photocure INC | $9,790.12 | 2023-2025 | Cysview |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $6,546.29 | 2022-2024 | Pylarify |
| Janssen Scientific Affairs, LLC | $5,679.01 | 2019-2024 | Erleada, Pipeline, Akeega |
| Astellas Pharma Global Development | $4,792.50 | 2023-2025 | Xtandi |
| Immunitybio, INC. | $4,027.36 | 2024-2025 | |
| Myovant Sciences INC. | $3,931.64 | 2021-2022 | |
| Procept Biorobotics Corporation | $3,512.42 | 2020-2024 | Aquabeam System, Aquabeam Robotic System |
| Johnson & Johnson Health Care Systems INC. | $2,970.00 | 2022 | |
| Abbvie INC. | $2,758.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $2,502.50 | 2025 | |
| Exelixis INC. | $1,980.00 | 2021 | |
| Genzyme Corporation | $1,851.61 | 2019-2022 | |
| Tolmar, INC. | $1,733.34 | 2023-2025 | Eligard, Jatenzo |
| Intuitive Surgical, INC. | $1,481.25 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $1,178.36 | 2022-2024 | Trelstar |
| Sumitomo Pharma America, INC. | $826.20 | 2023-2025 | Orgovyx, Gemtesa |
| Curium US LLC | $777.48 | 2025 | Detectnet |
| Medtronic, INC. | $769.23 | 2022-2024 | Interstim |
| Ferring Pharmaceuticals INC. | $751.38 | 2019-2025 | Adstiladrin, Firmagon |
| Boston Scientific Corporation | $459.29 | 2020-2025 | Spaceoar Vue System - 10ml, Ams 700, Rezum Generator |
| Teleflex LLC | $428.99 | 2022-2023 | Urolift |
| Janssen Research & Development, LLC | $266.12 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $224.61 | 2019-2024 | Yonsa |
| Bioprotect Medical, INC. | $165.12 | 2025 | Bioprotect Balloon Implant System |
| Neotract INC. | $158.06 | 2019-2020 | |
| Tempus Ai, INC | $148.20 | 2024 | |
| Histosonics, INC. | $146.49 | 2024 | |
| Axonics, INC. | $125.76 | 2022 | |
| Laborie Medical Technologies Corp. | $121.13 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Clovis Oncology, INC. | $116.64 | 2019-2020 | |
| Olympus America INC. | $113.94 | 2022-2025 | Itind System |
| Antares Pharma, INC. | $63.79 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Avation Medical, INC. | $44.84 | 2025 | Vivally System |
| Clarus Therapeutics INC. | $38.70 | 2021 | |
| Bk Medical Holding Company INC. | $31.31 | 2022 | |
| Coloplast Corp | $31.26 | 2019-2023 | Speedicath |
| Rochester Medical Corporation | $30.57 | 2019-2021 | |
| Urovant Sciences INC | $30.09 | 2022 | |
| Endo Pharmaceuticals INC. | $28.80 | 2019-2023 | Xiaflex |
| Ambu INC. | $24.65 | 2023 | |
| Angiodynamics, INC. | $23.92 | 2024 | Nanoknife |
| Civco Medical Instruments | $23.14 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $22.69 | 2025 | Bard Urinary Drainage Bag |
| Endo USA, INC. | $21.59 | 2024 | Xiaflex |
| Travere Therapeutics, INC. | $20.10 | 2019 | |
| Zyla Life Sciences, INC. | $19.16 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $17.95 | 2025 | |
| Smith+Nephew, INC. | $15.83 | 2025 | Stravix |
| Therapeuticsmd, INC. | $11.12 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,088.13 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hafron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.